The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms

Purpose: Hyperglycaemia-induced oxidative stress and inflammation contribute to vascular cell dysfunction and subsequent cardiovascular events in T2DM. Selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin significantly improves cardiovascular mortality in T2DM patients (EMPA-RE...

Descripción completa

Detalles Bibliográficos
Autores principales: Semo, Dilvin, Obergassel, Julius, Dorenkamp, Marc, Hemling, Pia, Strutz, Jasmin, Hiden, Ursula, Müller, Nicolle, Müller, Ulrich Alfons, Zulfikar, Sajan Ahmad, Godfrey, Rinesh, Waltenberger, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962711/
https://www.ncbi.nlm.nih.gov/pubmed/36835891
http://dx.doi.org/10.3390/jcm12041356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962711/
https://www.ncbi.nlm.nih.gov/pubmed/36835891
http://dx.doi.org/10.3390/jcm12041356

Ejemplares similares